Northwestern

1. Merck Sharp & Dohme Corporation $413,289 11 payments
2. Endotronix, Inc. $103,478 2 payments
3. SPR Therapeutics, Inc $98,867 3 payments
4. Exact Sciences Corporation $83,140 10 payments
5. Takeda Pharmaceuticals U.S.A., Inc. $13,341 2 payments
6. Amgen Inc. $1,420 1 payment
7. Genentech, Inc. $554 1 payment
8. Neurocrine Biosciences, Inc. $151 2 payments

1. A Phase 2, single arm study of CG0070 combined with pembrolizumab in subjects with Non-Muscle Invasive Bladder Cancer NMIBC unresponsive to Bacillus Calmette-Guerin BCG $188,400 2 payments
2. A Two-Arm, Open-label, Randomized Phase III Study of Pembrolizumab MK-3475 monotherapy versus standard chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer NPC Keynote-122 $177,925 6 payments
3. The SNAP Trial: SPRINT peripheral nerve stimulation for the treatment of Neuropathic post-Amputation Pain in a randomized, double-blinded, placebo-controlled, multicenter trial $98,867 3 payments
4. Tidal Study $83,140 10 payments
5. Proactive-Hf $53,925 1 payment
6. Proactive-Hf $49,553 1 payment
7. A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab MK-3475 versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine $46,964 3 payments
8. P1/3 talimogene laherparepvec + MK-3475 Combo melanoma $1,420 1 payment
9. An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients $554 1 payment
10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease $151 2 payments

1. Patient care $53,925 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.